

ClinicalTrials.gov Search Results 08/19/2022

	NCT Number	Title	Status	Study Results	Conditions	Interventions	Characteristics	Population	Locations
1	NCT05070351	<a href="#">Deprescribing Proton Pump Inhibitors to Reduce Post-TIPS Hepatic Encephalopathy</a>	Recruiting	No Results Available	•Hepatic Encephalopathy	•Drug: PPI deprescribing	Phase: •Phase 1 •Phase 2	Enrollment: 40	•Duke University Hospital, Durham, North Carolina, United States
2	NCT05279586	<a href="#">Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients</a>	Not yet recruiting	No Results Available	•Hepatic Encephalopathy	•Drug: lactulose •Drug: colistin	Phase: Early Phase 1	Enrollment: 316	
3	NCT04436601	<a href="#">Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Cirrhosis;(PEGHE Trial)</a>	Recruiting	No Results Available	•Hepatic Encephalopathy	•Drug: Polyethylene Glycols •Drug: Lactulose	Phase: Phase 4	Enrollment: 102	•Aga Khan University, Karachi, Sindh, Pakistan
4	NCT03420482	<a href="#">Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy</a>	Active, not recruiting	No Results Available	•Hepatic Encephalopathy	•Drug: Fecal Microbiota Transplant (FMT) oral capsules •Drug: Placebo oral capsule	Phase: Phase 2	Enrollment: 30	•Massachusetts General Hospital, Boston, Massachusetts, United States
5	NCT01846663	<a href="#">Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy</a>	Recruiting	No Results Available	•Hepatic Encephalopathy	•Drug: Placebo •Drug: Rifaximin	Phase: Phase 4	Enrollment: 100	•The University of Alabama at Birmingham, Birmingham, Alabama, United States  •Banner Research, Phoenix, Arizona, United States  •University Of Arizona Liver Research Institute, Tucson, Arizona, United States  •Southern California Liver Centers, Coronado, California, United States  •UCSD Clinical & Translational Research Institute, La Jolla, California, United States  •Loma Linda University Medical Center Transplantation Institute, Loma Linda, California, United States  •University of Southern Califorina Keck School Of Medicine, Los Angeles, California, United States  •Cedars-Sinai Medical Center, Los Angeles, California, United States  •Inland Empire Liver Foundation, Rialto, California, United States  •University of Colorado Denver, Aurora, Colorado, United States  •and 18 more
6	NCT04161053	<a href="#">Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy</a>	Recruiting	No Results Available	•Hepatic Encephalopathy	•Drug: Rifaximin •Drug: Nitazoxanide	Phase: Phase 3	Enrollment: 60	•Sherief Abd-Elsalam, Tanta, Egypt
7	NCT04899115	<a href="#">VE303 for Treatment of Hepatic Encephalopathy (HE)</a>	Recruiting	No Results Available	•Cirrhosis •Hepatic Encephalopathy	•Drug: Placebo •Drug: VE303 •Drug: oral vancomycin	Phase: Phase 2	Enrollment: 18	•University of Michigan, Ann Arbor, Michigan, United States
8	NCT04082780	<a href="#">Rifamycin in Minimal Hepatic Encephalopathy</a>	Recruiting	No Results Available	•Hepatic Encephalopathy •Cirrhosis, Liver	•Drug: Rifamycin SV MMX •Other: Placebo	Phase: Phase 2	Enrollment: 40	•Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States

	NCT Number	Title	Status	Study Results	Conditions	Interventions	Characteristics	Population	Locations
9	NCT03796598	<a href="#">FMT in Cirrhosis and Hepatic Encephalopathy</a>	Recruiting	No Results Available	<ul style="list-style-type: none"><li>•Cirrhosis</li><li>•Hepatic Encephalopathy</li></ul>	<ul style="list-style-type: none"><li>•Drug: Fecal Microbial transplant Capsules</li><li>•Drug: Fecal Microbial Transplant Enema</li><li>•Other: Placebo</li></ul>	Phase: <ul style="list-style-type: none"><li>•Phase 1</li><li>•Phase 2</li></ul>	Enrollment: 60	<ul style="list-style-type: none"><li>•Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia, United States</li></ul>
10	NCT04155099	<a href="#">Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy</a>	Recruiting	No Results Available	<ul style="list-style-type: none"><li>•Hepatic Encephalopathy</li><li>•Cirrhosis, Liver</li></ul>	<ul style="list-style-type: none"><li>•Biological: RBX7455</li><li>•Biological: Placebo</li></ul>	Phase: Phase 2	Enrollment: 75	<ul style="list-style-type: none"><li>•Ochsner Medical Center, Jefferson, Louisiana, United States</li></ul>
11	NCT05297448	<a href="#">Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis</a>	Recruiting	No Results Available	<ul style="list-style-type: none"><li>•Hepatic Encephalopathy</li></ul>	<ul style="list-style-type: none"><li>•Drug: Rifaximin SSD</li><li>•Drug: Placebo</li></ul>	Phase: Phase 3	Enrollment: 466	<ul style="list-style-type: none"><li>•Bausch Site 501, New Orleans, Louisiana, United States</li></ul>
12	NCT05071716	<a href="#">Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis</a>	Recruiting	No Results Available	<ul style="list-style-type: none"><li>•Hepatic Encephalopathy</li></ul>	<ul style="list-style-type: none"><li>•Drug: Rifaximin SSD</li><li>•Drug: Placebo</li></ul>	Phase: Phase 3	Enrollment: 466	<ul style="list-style-type: none"><li>•Bausch Site 001, Palmetto Bay, Florida, United States</li></ul>
13	NCT04244877	<a href="#">Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility</a>	Recruiting	No Results Available	<ul style="list-style-type: none"><li>•Cirrhosis, Liver</li><li>•Minimal Hepatic Encephalopathy</li><li>•Small Intestinal Bacterial Overgrowth</li><li>•Gastrointestinal Motility Disorder</li></ul>	<ul style="list-style-type: none"><li>•Drug: Rifaximin</li></ul>	Phase: Phase 3	Enrollment: 20	<ul style="list-style-type: none"><li>•Metrohealth Medical Center, Cleveland, Ohio, United States</li></ul>
14	NCT04073290	<a href="#">Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose</a>	Recruiting	No Results Available	<ul style="list-style-type: none"><li>•Hepatic Encephalopathy</li><li>•Cirrhosis, Liver</li><li>•Portal Hypertension</li><li>•Liver Diseases</li><li>•Pathological Processes</li></ul>	<ul style="list-style-type: none"><li>•Drug: Rifaximin 550 milligram Oral Tablet [XIFAXAN]</li><li>•Drug: Placebo oral tablet</li><li>•Drug: Lactulose 667 milligram/milliliter Oral Solution</li></ul>	Phase: Phase 4	Enrollment: 238	<ul style="list-style-type: none"><li>•Universitaire Ziekenhuizen Leuven, Leuven, Belgium</li><li>•Academic Medical Centre, Amsterdam, Netherlands</li><li>•University Medical Center Groningen, Groningen, Netherlands</li><li>•Leiden University Medical Center, Leiden, Netherlands</li><li>•Radboud University, Nijmegen, Netherlands</li><li>•Erasmus Medical Center, Rotterdam, Netherlands</li></ul>
15	NCT05128305	<a href="#">Integrated Traditional Chinese and Clinical Medicine for Chronic Hepatitis B and Its Complication</a>	Not yet recruiting	No Results Available	<ul style="list-style-type: none"><li>•Hepatic Encephalopathy</li><li>•Cirrhosis, Liver</li><li>•Portosystemic Shunt</li></ul>	<ul style="list-style-type: none"><li>•Drug: traditional Chinese medicine1 and traditional Chinese medicine 2</li></ul>	Phase: Phase 3	Enrollment: 276	<ul style="list-style-type: none"><li>•he First Affiliated Hospital of Shandong First Medical University &amp; Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China</li></ul>

	NCT Number	Title	Status	Study Results	Conditions	Interventions	Characteristics	Population	Locations
16	NCT04862221	<a href="#">Treatment for Immune Mediated Pathophysiology</a>	Recruiting	No Results Available	<ul style="list-style-type: none"><li>•Acute Liver Failure</li><li>•Fulminant Hepatic Failure</li><li>•Hepatic Encephalopathy</li><li>•Acute Liver Injury</li><li>•Immune Dysregulation</li></ul>	<ul style="list-style-type: none"><li>•Drug: High-dose methylprednisolone</li><li>•Drug: Equine anti-thymocyte globulin</li><li>•Drug: Prednisolone</li><li>•Drug: Placebo for prednisolone</li><li>•Drug: Placebo for infusions</li><li>•Drug: Diphenhydramine</li><li>•Drug: Methylprednisolone</li></ul>	Phase: Phase 2	Enrollment: 160	<ul style="list-style-type: none"><li>•Children's Hospital Los Angeles, Los Angeles, California, United States</li><li>•Lucile Packard Children's Hospital, Palo Alto, California, United States</li><li>•University of California San Francisco Benioff Children's Hospital, San Francisco, California, United States</li><li>•Children's Hospital Colorado, Aurora, Colorado, United States</li><li>•Yale New Haven Children's Hospital, New Haven, Connecticut, United States</li><li>•Emory Children's Healthcare of Atlanta, Atlanta, Georgia, United States</li><li>•Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States</li><li>•Riley Hospital for Children, Indianapolis, Indiana, United States</li><li>•Children's Hospital Boston, Boston, Massachusetts, United States</li><li>•The Children's Mercy Hospital, Kansas City, Missouri, United States</li><li>•and 10 more</li></ul>
17	NCT05061992	<a href="#">A Trial to Improve Quality of Life in People With Cirrhosis</a>	Recruiting	No Results Available	<ul style="list-style-type: none"><li>•Cirrhosis</li></ul>	<ul style="list-style-type: none"><li>•Drug: Lactulose</li></ul>	Phase: <ul style="list-style-type: none"><li>•Phase 2</li><li>•Phase 3</li></ul>	Enrollment: 75	<ul style="list-style-type: none"><li>•University of Michigan, Ann Arbor, Michigan, United States</li></ul>
18	NCT04932577	<a href="#">Faecal Microbiota Transplantation for Liver Cirrhosis</a>	Recruiting	No Results Available	<ul style="list-style-type: none"><li>•Liver Cirrhosis</li></ul>	<ul style="list-style-type: none"><li>•Biological: Faecal microbiota transplantation</li><li>•Biological: Placebo</li></ul>	Phase: <ul style="list-style-type: none"><li>•Phase 2</li><li>•Phase 3</li></ul>	Enrollment: 220	<ul style="list-style-type: none"><li>•Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark</li></ul>

Active clinical trials in hepatic encephalopathy: something old, something new and something borrowed. Neurochemical Research.

Tiziano Balzano

HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales; Madrid, Spain  
Correspondence: [tbalzano.hmcinac@hmhospitales.com](mailto:tbalzano.hmcinac@hmhospitales.com)